Femasys, Inc. (FEMY)
NASDAQ:FEMY
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$0.31 - $1.29
Previous CloseN/A
Volume25.00K
Average Volume (3M)581.25K
Market Cap
$23.98M
Enterprise Value$7.12M
Total Cash (Recent Filing)$9.27M
Total Debt (Recent Filing)$4.70M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding60,390,686
10 Day Avg. Volume691,468
30 Day Avg. Volume581,248
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.94
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$1.50Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$6.51M
Bulls Say, Bears Say
Bulls Say
Improved Leverage In 2025Material reduction in debt-to-equity materially lowers near-term refinancing risk and interest burden, improving financial flexibility. For a development-stage medtech, this stronger capital structure extends runway for commercialization and reduces probability of distress-driven outcome over the next 2–6 months.
Experienced COO Hire To Scale CommercializationBringing a seasoned device operations leader with Medtronic/Terumo experience strengthens execution capability across manufacturing, quality and global supply chains. This raises the odds of smoother product launches, higher throughput and faster adoption of FemBloc/FemaSeed over the medium term.
Focused In‑office Women’s Health Product PortfolioTargeting in‑office, minimally invasive gynecologic and fertility procedures aligns with a structural shift away from hospital-based care, supporting recurring consumable sales and easier adoption by clinics. This business model can sustain revenue growth as outpatient trends persist.
Bears Say
Persistent Heavy Cash BurnConsistently large negative operating and free cash flow creates ongoing financing needs that limit self-funded growth. Over 2–6 months this necessitates dilutive financings or lender concessions, constraining strategic optionality and increasing execution risk for commercialization investments.
Persistent Losses And Deteriorating Gross ProfitNegative margins and a collapse in gross profit signal the company’s cost base and product mix aren’t yet scalable. Until gross margins recover, additional revenue risks translating directly into wider losses rather than sustainable profitability, limiting durable earnings improvement prospects.
Nasdaq Listing Risk And Potential DilutionActive listing deficiency and stated willingness to use reverse split indicate structural market access risk; combined with recent financing amendments and new warrants, this raises the probability of dilution and lender influence, which can impair shareholder value and hinder long-term liquidity.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $0.31 and its highest was $1.29 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $23.98M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is May 07, 2026 which is in 25 days.
How were Femasys, Inc.’s earnings last quarter?
Femasys, Inc. released its earnings results on Mar 31, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.11.
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 60,390,686 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Femasys, Inc. reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -0.714%.
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
FEMY Stock 12 Month Forecast
Average Price Target
$1.50
▲(105.48% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
3.06% Insiders
2.44% Mutual Funds
11.21% Other Institutional Investors
81.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---